Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and twelve pending patents, two of which are related to artificial intelligence.
Company profile
Ticker
TVGN, TVGNW
Exchange
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Amgen • GE Vernova • Gilead Sciences • ADT • Li Auto • Burford Capital Limited • NIO • Opendoor • GoHealth • BrightSphere Investment ...
Former names
Semper Paratus Acquisition Corp
SEC CIK
Corporate docs
IRS number
981597194
TVGN stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
26 Aug 24
8-K/A
Entry into a Material Definitive Agreement
26 Aug 24
424B3
Prospectus supplement
23 Aug 24
8-K
Entry into a Material Definitive Agreement
23 Aug 24
424B3
Prospectus supplement
14 Aug 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
424B3
Prospectus supplement
5 Aug 24
EFFECT
Notice of effectiveness
5 Aug 24
S-1/A
IPO registration (amended)
31 Jul 24
S-1/A
IPO registration (amended)
23 Jul 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.14 mm | 1.14 mm | 1.14 mm | 1.14 mm | 1.14 mm | 1.14 mm |
Cash burn (monthly) | 60.84 k | 193.44 k | 2.87 mm | 3.28 mm | 994.17 k | 177.34 k |
Cash used (since last report) | 197.41 k | 627.69 k | 9.30 mm | 10.65 mm | 3.23 mm | 575.44 k |
Cash remaining | 937.98 k | 507.70 k | -8.17 mm | -9.51 mm | -2.09 mm | 559.95 k |
Runway (months of cash) | 15.4 | 2.6 | -2.8 | -2.9 | -2.1 | 3.2 |
Institutional ownership, Q1 2024
7.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 40 |
Opened positions | 40 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 6.47 bn |
Total shares | 13.55 mm |
Total puts | 0.00 |
Total calls | 140.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Parallax Volatility Advisers | 2.85 mm | $234.81 mm |
FourWorld Capital Management | 1.45 mm | $5.44 bn |
Corbin Capital Partners | 1.16 mm | $95.70 mm |
Calamos Advisors | 1.00 mm | $70.00 mm |
Polar Asset Management Partners | 717.31 k | $59.12 mm |
MMCAP International Inc. SPC | 650.00 k | $53.63 mm |
Linden Advisors | 650.00 k | $51.68 mm |
Periscope Capital | 608.90 k | $50.23 mm |
HGC Investment Management | 575.39 k | $47.47 mm |
D. E. Shaw & Co. | 308.00 k | $21.56 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Jun 24 | Kirti Desai | Common Stock | Buy | Acquire P | No | No | 0.82 | 3,000 | 2.46 k | 9,699,186 |
5 Jun 24 | Ryan H. Saadi | Common Stock | Buy | Acquire P | No | No | 0.7671 | 2,607.322 | 2.00 k | 118,252,659.322 |
14 Feb 24 | Kirti Desai | Common Stock | Grant | Acquire A | No | No | 0 | 9,696,186 | 0.00 | 9,696,186 |
14 Feb 24 | Keow Lin Goh | Common Stock | Grant | Acquire A | No | No | 0 | 193,923 | 0.00 | 193,923 |
14 Feb 24 | Curtis L. Patton | Common Stock | Grant | Acquire A | No | No | 0 | 969,618 | 0.00 | 969,618 |
News
Tevogen Bio Highlights Achievements And Assets, Potentially Serving As A Blueprint To Drive Sustainable Innovation And Maintain The U.S.'s Competitive Edge In The Biotech Sector
24 Sep 24
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
10 Sep 24
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
26 Aug 24
Tevogen Bio Secures $6M Series C Preferred Stock Investment With The Patel Family, LLP
22 Aug 24
Tevogen Bio Holdings Q2 EPS $(0.04) Up From $(0.18) YoY
15 Aug 24
Press releases
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
24 Sep 24
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
22 Aug 24
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
15 Aug 24
Tevogen Bio's Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
14 Aug 24
Tevogen Bio's Founding CEO, Ryan Saadi, Expresses Conviction in Company's Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
9 Aug 24